Can big data predict heart disease before today’s doctors can? IBM thinks so.
Cameron Health, a San Clemente, Calif., medical-device maker, has raised $14.1 million of a planned $50 million fifth funding round, I’ve learned. The company is working on a new type of implantable defibrillator that’s designed to be easier to implant and program than existing models.
Featured companies: Cerus, LabNow, Reliant Pharmaceuticals
(UPDATED: See below.)
Featured companies: DirectFlow, Direvo, Indigo Biosystems, MacroGenics
Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics
Featured companies: BioVascular, Carefx, ClinResearch, Healthcare Management Directions, NanoCor, OxyPlus, Revitus, Spotlight Surgical, United BioSource
(UPDATED at 12:30pm PT — see below.)
Arm wrestling over drug patents – Three months ago, the military government running Thailand informed Abbott Laboratories that it intended to break the company’s patents on several expensive drugs, including the HIV protease inhibitor Kaletra, thus allowing the manufacture or import of cheaper knockoffs. Abbott responded by dropping its plans to bring newer drugs, including a heat-resistant version of Kaletra, to Thailand, and the pharma and the junta have been locked in a standoff ever since. Over the weekend, Abbott offered to make the new version of Kaletra available at a deep discount price if Thailand left its patents alone; so far the government hasn’t responded.
[Editor's note: David Hamilton, a former Wall Street Journal reporter, has covered the biotech sector for years and we're delighted to have him as a contributor on news and trends in biotech, health and science (we've already run a few of his pieces). Biotech and health start-ups haven't been a VentureBeat focus, but they're important. We plan to create a separate forum for his work, and point to his more important stuff from VentureBeat.]
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)